Womenra
$ 50,00 – $ 300,00Price range: $ 50,00 through $ 300,00
Xeloda
$ 494,00 – $ 788,00Price range: $ 494,00 through $ 788,00
Xalatan
$ 74,00 – $ 405,00Price range: $ 74,00 through $ 405,00
Xalatan is a sterile ophthalmic solution primarily used to lower high pressure inside the eye. This medication is specifically indicated for patients suffering from open-angle glaucoma or ocular hypertension. The active ingredient works by increasing the natural outflow of aqueous humor, which is the fluid that maintains the eye’s internal pressure. By effectively managing intraocular pressure, Xalatan helps protect the optic nerve and supports overall long-term vision health. This eye drop is designed for convenient once-daily administration to provide consistent results for maintaining ocular stability.
Active substance: xalatan
SKU:
Xalatan
Category: Eye Care
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM
Each dosage option has its own packaging choices.
Description
Xalatan belongs to a group of ophthalmic medications known as prostaglandin analogs. The active substance, latanoprost, works by enhancing the natural drainage of fluid from inside the eye to lower intraocular pressure. This prescription medication is authorized by the Food and Drug Administration (FDA) for the treatment of specific ocular conditions in the United States.
Topical ocular administration of prostaglandin analogs requires precise adherence to prescribed dosing routines to achieve sustained therapeutic efficacy. Regular monitoring by an eye care professional ensures that intraocular pressure target levels are maintained over long-term treatment periods.
| Parameter | Details |
|---|---|
| Drug name | Xalatan |
| Active ingredient (INN) | Latanoprost |
| Therapeutic class | Prostaglandin F2-alpha analog |
| Dosage form | Ophthalmic solution (0.005%) |
| Route of administration | Topical (eye drop) |
| Primary purpose | Reduction of elevated intraocular pressure |
| Prescription status | Prescription (Rx) only |
Main uses
Xalatan is indicated for the reduction of elevated intraocular pressure (IOP) in patients diagnosed with open-angle glaucoma or ocular hypertension. Sustained elevation of intraocular pressure represents a primary risk factor for progressive optic nerve damage and subsequent visual field loss. By effectively lowering pressure inside the eye, Xalatan helps mitigate the risk of irreversible vision impairment associated with these chronic conditions. The medication is prescribed when baseline intraocular pressure measurements exceed normal physiological ranges and clinical assessment warrants therapeutic intervention. In pediatric patients or individuals with angle-closure glaucoma, prescribing decisions require specialized ophthalmological evaluation, as efficacy and safety parameters differ across clinical sub-populations.
How the drug works
The active constituent of Xalatan is latanoprost, an ester prodrug that functions as a selective prostanoid FP receptor agonist. Upon topical administration into the conjunctival sac, latanoprost is absorbed through the cornea, where endogenous esterases hydrolyze it into biologically active latanoprost acid. The active acid form selectively binds to FP receptors located within the ciliary muscle and trabecular meshwork. This binding alters extracellular matrix structure and relaxes ciliary muscle fibers, thereby increasing the uveoscleral outflow of aqueous humor. By facilitating liquid drainage out of the anterior chamber without significantly altering aqueous humor production or systemic blood pressure, Xalatan lowers intraocular pressure consistently over a 24-hour period.
Pharmacokinetic Profile and Administration
What happens in the body
Following topical ocular application, latanoprost penetrates the cornea efficiently. Maximal concentration of the active latanoprost acid within the aqueous humor is achieved approximately two hours after administration. The systemic absorption of latanoprost acid into the vascular circulation is minimal, with peak plasma concentrations occurring within five minutes post-instillation. The plasma elimination half-life of latanoprost acid is short, measuring approximately 17 minutes in human plasma. The volume of distribution is estimated at 0.16 L/kg. The active metabolite undergoes rapid metabolism primarily by the liver via fatty acid beta-oxidation into 1,2-dinor and 1,2,3,4-tetranor metabolites. Excretion occurs predominantly through the kidneys, with approximately 88% of the administered dose recovered in urine following local administration.
Dosing schedule
The standard recommended dosage of Xalatan is one drop placed into the affected eye or eyes once daily, administered in the evening. Adherence to an evening dosing regimen has demonstrated optimal efficacy in lowering intraocular pressure compared to morning administration. Dosages exceeding the recommended once-daily regimen must be avoided, as more frequent administration of prostaglandin analogs may paradoxically decrease the pressure-lowering effect or cause increased intraocular pressure spikes. If Xalatan is prescribed alongside other topical ophthalmic drugs, each medication should be administered at least five minutes apart to prevent dilution of active components. Contact lenses must be removed prior to instillation of the drops and may be reinserted 15 minutes after administration.
First days of treatment
When initiating therapy with Xalatan, the reduction in intraocular pressure typically begins approximately 3 to 4 hours after administration, reaching its peak effect between 8 and 12 hours. During the initial days of treatment, patients may experience mild, transient ocular sensations such as localized hyperemia, mild stinging, or a temporary feeling of a foreign body in the eye. These initial localized responses generally stabilize as therapy continues. Ophthalmologists usually evaluate the therapeutic response between two to four weeks after starting Xalatan to measure the precise drop in intraocular pressure and verify treatment efficacy.
If you skip a dose
If a dose of Xalatan is missed in the evening, treatment should proceed with the next scheduled dose the following evening as planned. Patients must not instill extra drops or double the dose to compensate for the skipped application. Administering multiple drops within a 24-hour period can compromise the drug’s therapeutic efficacy and increase the likelihood of local side effects such as severe ocular redness or discomfort. Maintaining a consistent daily routine helps ensure steady regulation of intraocular pressure over time.
Day-to-day use
Proper administration technique is essential for day-to-day use to maintain sterility and optimal drug delivery. Patients should wash their hands thoroughly before applying the solution. Care must be taken to prevent the tip of the applicator bottle from touching the eye, eyelids, fingers, or any external surface to avoid microbial contamination. Following instillation, applying gentle pressure to the nasolacrimal duct (punctal occlusion) at the inner corner of the eye for one to two minutes reduces systemic absorption of latanoprost acid and enhances localized ocular retention.
Safety Profile and Precautions
Compatibility with other medicines
In vitro studies have demonstrated that precipitation occurs when eye drops containing thimerosal are mixed directly with Xalatan. Therefore, if thimerosal-containing ophthalmic preparations are used concurrently, they must be administered at least five minutes apart. Concomitant administration of two or more topical prostaglandin analogs, prostaglandin derivatives, or prostamides is not recommended, as paradoxical elevations in intraocular pressure have been documented. Xalatan can be safely co-administered with other classes of topical intraocular pressure-lowering agents, such as beta-adrenergic antagonists (e.g., timolol), carbonic anhydrase inhibitors, and alpha-adrenergic agonists, provided appropriate time intervals are observed between drop instillations.
Adverse reactions
Xalatan is associated with specific local ocular adverse reactions. The most common adverse effect reported in clinical trials is iris pigmentation change, which occurs due to an increased amount of melanin in the stromal melanocytes rather than an increase in melanocyte count. This hyperpigmentation is usually permanent and leads to a gradual brown discoloration of the iris. Additional localized side effects include eyelash changes (increased length, thickness, pigmentation, and number of lashes), conjunctival hyperemia, eye pruritus, burning, stinging, punctate keratitis, and foreign body sensation. Systemic adverse reactions are infrequent but may include upper respiratory tract infections, chest pain, and mild skin rashes. Macular edema, including cystoid macular edema, has been reported primarily in aphakic patients, pseudophakic patients with a torn posterior lens capsule, or individuals with known risk factors for macular edema.
Important precautions
Xalatan should be used with caution in patients with active intraocular inflammation, such as iritis or uveitis, as the medication may exacerbate inflammatory processes. Patients should be informed about the potential for progressive, permanent iris pigmentation changes and periorbital tissue darkening before beginning therapy. Unilateral treatment may result in permanent heterochromia (different colored eyes). In pregnant women, Xalatan should be used only if the potential benefit justifies the potential risk to the fetus, as adequate clinical studies in pregnant individuals are lacking. It is not definitively known whether latanoprost acid is excreted in human milk; caution is advised when administering to nursing mothers. Safety and effectiveness in pediatric patients under 1 year of age have not been established.
Storage and expiration
Unopened bottles of Xalatan must be stored under refrigeration between 2°C and 8°C (36°F to 46°F) and protected from light. Once a bottle is opened for patient use, it may be stored at room temperature up to 25°C (77°F) for up to 6 weeks. The bottle should be kept tightly closed when not in use. Patients should disallow usage of the product beyond the printed expiration date or after the 6-week open-bottle limit has elapsed. Products showing visible discoloration or turbidity must be safely discarded.
Common questions
Q: Will Xalatan permanently change my eye color?
Yes, Xalatan can cause a gradual increase in brown pigment in the iris. This change is typically permanent and may not be noticeable until several months or years of continuous use. If only one eye is treated, a permanent difference in color between the eyes may occur.
Q: Can Xalatan be used while wearing contact lenses?
Contact lenses must be removed prior to instilling Xalatan drops because the solution contains benzalkonium chloride, a preservative that can be absorbed by soft contact lenses. Lenses may be reinserted 15 minutes after administering the eye drop.
Q: What happens if I use Xalatan twice a day instead of once a day?
Using Xalatan more frequently than once daily can lessen its ability to lower intraocular pressure. Excessive use may actually cause a paradoxical increase in eye pressure and worsen local side effects like redness and irritation.
Q: Is it safe to drive after applying Xalatan eye drops?
Xalatan may cause temporary blurred vision or mild eye discomfort immediately following application. Patients should refrain from driving or operating machinery until their vision has fully cleared.
Q: How long does it take for Xalatan to lower intraocular pressure?
The pressure-lowering effect begins approximately 3 to 4 hours after administration, with maximum efficacy reached within 8 to 12 hours. Full therapeutic assessment usually takes place after 2 to 4 weeks of daily evening use.
This text is for informational purposes only and does not constitute individual medical advice.
In accordance with FDA requirements.
Additional information
| Dosage |
2.5ml |
|---|---|
| Package |
1 bottles ,2 bottles ,3 bottles ,4 bottles ,5 bottles ,6 bottles ,7 bottles ,8 bottles ,9 bottles ,10 bottles |
| Ενεργός Ουσία |
Related products
Careprost
$ 42,00 – $ 367,00Price range: $ 42,00 through $ 367,00
Active substance: Bimatoprost
More Details
This product has multiple variants. The options may be chosen on the product page
Cyclogyl
$ 32,00
Active substance: Cyclopentolate ophthalmic
More Details
This product has multiple variants. The options may be chosen on the product page
Diamox
$ 60,00 – $ 144,00Price range: $ 60,00 through $ 144,00
Active substance: Acetazolamide
More Details
This product has multiple variants. The options may be chosen on the product page
Lumigan
$ 53,00 – $ 490,00Price range: $ 53,00 through $ 490,00
Active substance: Bimatoprost
More Details
This product has multiple variants. The options may be chosen on the product page
Norwayz
$ 49,00 – $ 69,00Price range: $ 49,00 through $ 69,00
Active substance: Idebenone
More Details
This product has multiple variants. The options may be chosen on the product page
Ophthacare
$ 49,00
Active substance: Damask Rose, Honey
More Details
This product has multiple variants. The options may be chosen on the product page
Patanol eye
$ 10,00 – $ 40,00Price range: $ 10,00 through $ 40,00
Active substance: Olopatadine
More Details
This product has multiple variants. The options may be chosen on the product page
Toba Eye Drops
$ 11,00 – $ 31,00Price range: $ 11,00 through $ 31,00
Active substance: Tobramycin
More Details
This product has multiple variants. The options may be chosen on the product page
